Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336023 · ClinicalTrials.gov registry record · Phase 3
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,663
- Enrollment target
- 20
- Study locations
NCT01336023: Completed Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
NCT01336023 is a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,663 participants, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01336023, a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,663 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.
Primary Outcome
Values of mean change in HbA1c.
Conditions Studied
Interventions
- DRUG liraglutide
- DRUG insulin degludec
- DRUG insulin degludec/liraglutide
Study Locations (20)
California
- Novo Nordisk Investigational Site - Anaheim
- Novo Nordisk Investigational Site - Bermuda Dunes
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Encino
- Novo Nordisk Investigational Site - Fair Oaks
- Novo Nordisk Investigational Site - Fresno
- Novo Nordisk Investigational Site - Greenbrae
- Novo Nordisk Investigational Site - La Jolla
- Novo Nordisk Investigational Site - Long Beach
- Novo Nordisk Investigational Site - Los Angeles
- Novo Nordisk Investigational Site - Montclair
- Novo Nordisk Investigational Site - Monterey
- Novo Nordisk Investigational Site - Orange
- Novo Nordisk Investigational Site - Poway
- Novo Nordisk Investigational Site - San Diego
- Novo Nordisk Investigational Site - San Diego
- Novo Nordisk Investigational Site - San Diego
- Novo Nordisk Investigational Site - San Mateo
- Novo Nordisk Investigational Site - Santa Barbara
Alabama
- Novo Nordisk Investigational Site - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,663 participants |
| Start Date | 2011-05-23 |
| Est. Completion | 2012-11-22 |
| Phase | Phase 3 |
What the finished NCT01336023 record still lists
NCT01336023 is an interventional study that assigns participants to a tested intervention. Its 1,663 participants enrollment target places it among the larger protocols in the corpus, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which liraglutide is the first listed.
NCT01336023 names 20 study sites across 2 states, led by California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01336023 about?
NCT01336023 is a clinical study titled "Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes". This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metfor...
What is the current status of trial NCT01336023?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,663 participants. The study started on 2011-05-23. Estimated completion is 2012-11-22.
What conditions does trial NCT01336023 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.
What interventions are being tested in trial NCT01336023?
The interventions under investigation include: liraglutide (DRUG), insulin degludec (DRUG), insulin degludec/liraglutide (DRUG).
Who is sponsoring clinical trial NCT01336023?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01336023 being conducted?
This trial has 20 study locations across Alabama, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01336023's enrollment target sits among peer trials
1,663 20th of 348 higher than 329 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI